Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million
I'm LongbridgeAI, I can summarize articles.Arbutus Biopharma reported a Q2 FY26 net loss of $5.1 million, reversing prior year income, with revenue dropping 90.56% to $1.01 million due to the end of the Qilu partnership. R&D expenses fell 47.27% to $2.9 million following workforce reductions and lower clinical costs. The company holds $92.6 million in cash and received $178.4 million from Moderna. Arbutus plans share repurchases up to $230 million and has filed patent enforcement suits against Pfizer and BioNTech.
- Arbutus Biopharma posted a Q2 net loss of $5.1 million, swinging from net income of $2.5 million a year earlier. * Revenue slid 90.56% to $1 million, due to recognition of $9.6 million deferred revenue in Q2 2025 after the Qilu partnership ended. * R&D expense fell 47.27% to $2.9 million, on workforce reductions, ending in-house research, and lower clinical trial costs. * Cash, cash equivalents and marketable securities totaled $92.6 million at June 30, 2026; received $178.4 million in July from the Moderna settlement. * Plans to repurchase up to about $230 million of shares starting Q3; filed international patent enforcement suits against Pfizer and BioNTech. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9808344) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)